

Date of Submission: 5th August 2021

To,

The Secretary

Listing Department

BSE Limited

Department of Corporate Services

Phiroze Jeejeebhoy Towers,

Dalal Street, Mumbai - 400 001

Scrip Code - 539551

To,

The Secretary

Listing Department

National Stock Exchange of India Limited

Exchange Plaza, Bandra Kurla Complex

Mumbai - 400 050

Stock Code- NH

Dear Sir/Madam,

Sub: Investor Presentation for the First Quarter ended 30th June 2021

With reference to the subject, please find enclosed Investor Presentation for the First Quarter ended 30th June 2021.

Kindly take the above information on record.

Yours faithfully,

For NARAYANA HRUDAYALAYA LIMITED

See alean) Sridhar S

Group Company Secretary, Legal and Compliance Officer





Investor Presentation

August 2021



Important Disclosure

No representation or warranty, express or implied is made as to, and no reliance should be placed on, the fairness, accuracy, completeness or correctness of such information or opinions contained herein. The information contained in this presentation is only current as of its date. Certain statements made in this presentation may not be based on historical information or facts and may be "forward looking statements", including those relating to the Company's general business plans and strategy, its future financial condition and growth prospects, and future developments in its industry and its competitive and regulatory environment.

Actual results may differ materially from these forward-looking statements due to a number of factors, including future changes or developments in the Company's business, its competitive environment and political, economic, legal and social conditions in India.

This communication is for general information purpose only, without regard to specific objectives, financial situations and needs of any particular person. This presentation does not constitute an offer or invitation to purchase or subscribe for any shares in the Company and neither any part of it shall form the basis of or be relied upon in connection with any contract or commitment whatsoever. The Company may alter, modify or otherwise change in any manner the content of this presentation, without obligation to notify any person of such revision or changes. This presentation can not be copied and/or disseminated in any manner.



NH at a Glance

As on 30th June 2021

46	Healthcare Facilities	Operational beds
20	Owned / Operated Hospitals ⁽¹⁾	5,442 Beds
1	Managed Hospital ⁽²⁾	112 Beds
5	Heart Centres ⁽³⁾	318 Beds
19	Primary Healthcare Facilities ⁽⁴⁾	10 Beds
1	Hospital in Cayman Islands	110 Beds



6,725	Capacity Beds
5,992 ⁽⁵⁾	Operational Beds
3.2 mn ⁽⁶⁾	Average Effective Capital Cost per Operational Bed



30+ Specialities




17,003

Full-time Employees and Associates including 3,589 doctors

- (1) NH owns the P&L responsibility
- (2) NH manages 3rd party hospital for Management Fees
- (3) Including 1 heart centre in Chittagong, Bangladesh
- (4) Includes clinics, information centres, etc
- (5) In FY21, exited operations at CNH Heart Centre (39 operational beds) wef 1st April 2020 and St Marthas (27 operational beds) in December 2020
- (6) Based on (Gross Block for Fixed Assets (adjusted for non-cash government grant provision, non-cash financial lease for Dharamshila unit)+ Capital Work in Progress (CWIP)) / Number of operational beds as of June 30th 2021 but excluding Managed Hospitals and Cayman facility

NH's footprint in India





Key Highlights – Q1 FY22....(1/2)



Clinical & Operational

- NH SRCC, Mumbai successfully performed its first pre-natal intervention for Twin-to-Twin Transfusion Syndrome (TTTS)
- Mazumdar Shaw Medical Centre, Bengaluru continues to build on its eminence in solid organ transplants and other complex procedures and performed 12 renal transplants, 5 liver transplants and 20 robotic surgeries in the first quarter of the fiscal
- Narayana Multispeciality Hospital, Mysore performed Cytoreductive Surgery + Hyperthermic Intraperitoneal Chemotherapy (CRS+HIPEC) for advanced ovarian cancer, it is the first hospital in the region to perform such a procedure
- Narayana Superspeciality Hospital, Howrah performed the region's first adult heart transplant (previous two heart transplants were done on paediatric patients)
- In the first reported case in India, Narayana Multispeciality Hospital, Ahmedabad performed a rare procedure, Melody in Mitral position on a 2-year-old child suffering from severe mitral regurgitation with single papillary muscle



- Consolidated operating revenues of INR 8,598 mn in Q1 FY22, an increase of 118.5% YoY
- Consolidated EBITDA of INR 1,404⁽¹⁾ mn in Q1 FY22 translating into EBITDA margin of 16.3% and consolidated PAT of INR 762⁽²⁾ mn at a PAT margin of 8.9%
- Consolidated Total Borrowings less Cash and Bank Balance of INR 4,280 mn as on 30th June 2021, reflecting net debt to equity ratio of 0.36 (Out of which, debt worth US\$ 37.3 mn is foreign currency denominated)
- (1) As per the new accounting treatment for leases per IND AS 116 effective 1st April 2019 which resulted in INR 138 mn increase in EBITDA for Q1 FY22
- (2) As per the new accounting treatment for leases per IND AS 116 effective 1st April 2019 which resulted in INR 4 mn decrease in PAT for Q1 FY22



Key Highlights – Q1 FY22(2/2)



- Implemented chat functionality during video consultation and instant refunds to improve patient experience
- Enabled IVR based family communication feature in AADI (Aathma Application for Doctor Insights) Doctor's application to ensure timely communication with patients' families
- Implemented Neuro Imaging Stroke Artificial Intelligence (AI) Platform for Health City Cayman Islands
- Implemented visual item detection of medicines in our consumables pilot program with an aim to reduce errors and improve efficiency
- Implemented patient analytics dashboards for the patient service excellence group to analyze and improve upon waiting periods across consultation, lab and radiology departments
- Implemented AI based chest X-ray anomaly detection pilot program on AADI Doctor's App



- Achieved energy savings worth INR 9.0 mn at Health City, Bengaluru through captive alternate energy sourcing channels
- Achieved energy savings worth INR 3.2 mn through upgradation of equipment at Health City, RTIICS, Dharamshila and Ahmedabad facilities
- Conducted thermography, electrical safety and energy audit at Health City, Bengaluru



Covid-19 Vaccination Program – Q1 FY22

Dr Shetty does not believe that we should make a profit out of vaccinating the nation against COVID-19. As I part of our mission to make healthcare accessible to all, our hospitals administer vaccines at the cost of procurement. We have also partnered with several NGOs and global corporates to sponsor free vaccines for the underprivileged.

Total Vaccines Administered

Total Vaccine Revenues

Vaccine Consumption Cost

Free Vaccines Administered

478,880

INR 214 mn

INR 179 mn

12,660⁽¹⁾










(1) Free vaccination program commenced in mid-May, 2021




Revenue Mix – India (Q1 FY22)





- (1) NH owns the P&L responsibility
- (2) Includes managed hospital, clinics, learning and development, teleradiology, etc
- (3) As percentage of IP and OP revenue, excludes Jammu VGF, clinics, other ancillary business
- (4) Insured Patients include Insurance-covered patients, corporate patients (including public sector undertakings); Schemes include CGHS, ESIS, other state government schemes
- (5) Calculated on operating revenue of owned / operated hospitals
- (6) Percentages might not add upto 100% due to rounding off


■ Western











⁽¹⁾ OP figures include day-care business but does not include Vaccine footfalls (Double line graphs are not to scale)


⁽²⁾ ARPOB for the period Q1 FY21 was INR 10.5 mn and INR 11.2 mn for Q1 FY22

⁽³⁾ Footfalls for IP correspond to Discharges


⁽⁴⁾ Includes critical care and step-down care beds




Operational Review – Cayman Islands










- (1) OP figures include day-care business (Double line graph is not to scale)
- (2) ARPOB for the period Q1 FY21 was USD 1.6 mn and USD 1.9 mn for Q1 FY22
- (3) ALOS for the period Q1 FY21 was 8.0 days and 6.6 days for Q1 FY22



Regional Split – India (Q1 FY22)

This considers owned/operated hospitals in India (excl. Jammu)





Maturity Profile – India (Q1 FY22)

This considers owned/operated hospitals in India (excl. Jammu)⁽¹⁾


Maturity	Hospitals (Exc. Managed Hospital & Jammu)	Hospital Operating Revenues	% of Hospital Operational Beds	Key Performance Indicators
Existing	16	% of Total YoY Growth 86% 129%	89%	ARPOB (INR mn) Discharges ⁽²⁾ EBITDAR Margin ⁽³⁾ 10.8 10.8
New	3	143%	11%	14.3 3,791 -0.5%


New: Mumbai, Delhi and Gurugram units

- (1) Jammu facility reported operational revenues of INR 277 mn
- (2) ALOS of matured set is 5.6 days and new units is 6.0 days
- (3) EBITDA before rental/revenue share and before allocation of any corporate expenses



Profitability Snapshot – India





Categories have been calculated as

Consumable Expenses = Purchase of medical consumables, drugs and surgical equipment net of changes in inventories of medical consumables, drugs and surgical equipment; Manpower (Employees and Doctors) expenses = Employee benefits + Professional fees to doctors;

Overhead expenses = all other expenses

⁽¹⁾ Denotes EBITDA for India business

⁽²⁾ Denotes EBITDA margin for India business

⁽³⁾ Denotes EBITDA margin for India business adjusted for new centres

⁽⁴⁾ EBITDA before rental/revenue share and before allocation of any corporate expenses



Consolidated Financial Performance

Figures in INR mn, unless stated otherwise

Drofit and	Loss Stateme	ant(1,3)
Pront and	LOSS Statem	en (

Tront and 2000 Statement			
Particulars (INR mn)	Q1 FY21	Q1 FY22	
Total Operating Revenue	3,935	8,598	
Consumption	1,105	2,154	
Doctors Expenses	1,165	1,708	
Employee (Excluding Doctors) Expenses	1,396	1,690	
Other Admin Expenses	1,179	1,709	
Total Expenses	4,845	7,261	
Other Income	47	67	
EBITDA	(863) ⁽⁴⁾	1,404 ⁽⁴⁾	
Depreciation and Amortization	464	447	
Finance Costs	197	171	
Share of (loss)/profit of equity accounted investees	(10)	(14)	
PBT	(1,534)	771	
Tax Expense	(337)	9	
PAT	(1,198)	762	
Total Comprehensive Income	(1,199)	795	


Particulars	30 th June 2021
Shareholder Equity	11,998
Total Borrowings	5,812
Lease Liability	2,014
Net Block + CWIP	16,611(2)
Goodwill	581
Right to Use Assets	1,931
Net Receivables	3,177
Current Investment	1,527
Cash and Bank Balance	1,532

As on June 30th, 2021, Total Borrowings less Cash and Bank Balance was Rs 4,280 mn, representing a net debt to equity ratio of 0.36 (Out of which, debt worth US\$ 37.3 mn is foreign currency denominated)

- (1) Figures might not equal the reported numbers due to rounding off
- (2) Net Block includes non-cash government grant impact of INR 1,221 mn and non-cash financial lease impact of INR 891 mn
- (3) As per the new accounting treatment for leases per IND AS 116 effective 1st April 2019 which resulted in INR 102 mn increase in depreciation, INR 41 mn increase in finance cost resulting in decrease of INR 4 mn in PAT for Q1 FY 22 on a like-to-like basis (pre-IND AS 116)
- (4) Heart centre at Chittagong incurred an operational loss of INR 12 mn, Hospital Management project in St. Lucia generated an operational profit of INR 46 mn and Software Development project in North America generated an operational profit of INR 1 mn in Q1 FY22 while Chittagong heart centre incurred loss of INR 5 mn while St.Lucia and North America project had not commenced in Q1 FY21

Shareholding Pattern





Total Number of Shares

204,360,804

Key DIIs

SBI Asset Management

Axis Asset Management

Nippon Life India Asset Management

UTI Asset Management

DSP Investment Management

Key Flls

Wellington Asset Management

Kuwait Investment Authority

Vanguard Index Fund

Mirae Asset Management

Franklin Templeton Asset Management